{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:17:51Z","timestamp":1792189071845,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021872","name":"Office of Population Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002407","name":"Women Helping Others Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omtm.2024.101312","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:15:01Z","timestamp":1722975301000},"page":"101312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model"],"prefix":"10.1016","volume":"32","author":[{"given":"Megan C.","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibi B.","family":"Likhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence S.","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison R.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101312_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000516752","article-title":"Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants","volume":"55","author":"Brown","year":"2021","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.omtm.2024.101312_bib2","unstructured":"ALSoD. https:\/\/alsod.ac.uk\/."},{"key":"10.1016\/j.omtm.2024.101312_bib3","doi-asserted-by":"crossref","first-page":"1709.e3","DOI":"10.1016\/j.neurobiolaging.2012.10.027","article-title":"Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene","volume":"34","author":"Tortelli","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.omtm.2024.101312_bib4","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1089\/ars.2009.2536","article-title":"Aggregation of Copper\u2013Zinc Superoxide Dismutase in Familial and Sporadic ALS","volume":"11","author":"Chattopadhyay","year":"2009","journal-title":"Antiox. Redox Signal."},{"key":"10.1016\/j.omtm.2024.101312_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-31773-z","article-title":"Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis","volume":"8","author":"Par\u00e9","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101312_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.1123511","article-title":"Onset and progression in inherited ALS determined by motor neurons and microglia","volume":"312","author":"Boill\u00e9e","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101312_bib7","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0802556105","article-title":"Mutant SOD1 in cell types other\u00a0than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice","volume":"105","author":"Yamanaka","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101312_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn2047","article-title":"Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis","volume":"11","author":"Yamanaka","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.1314085111","article-title":"Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS","volume":"111","author":"Meyer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101312_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.stem.2008.10.001","article-title":"Non-Cell-Autonomous Effect of Human SOD1G37R Astrocytes on Motor Neurons Derived from Human Embryonic Stem Cells","volume":"3","author":"Marchetto","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtm.2024.101312_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nbt.1957","article-title":"Astrocytes from familial and sporadic ALS patients are toxic to motor neurons","volume":"29","author":"Haidet-Phillips","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2024.101312_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non\u2013cell autonomous effect of glia on motor neurons in an embryonic stem cell\u2013based ALS model","volume":"10","author":"Di Giorgio","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13041-017-0300-4","article-title":"Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms","volume":"10","author":"Madill","year":"2017","journal-title":"Mol. Brain"},{"key":"10.1016\/j.omtm.2024.101312_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","article-title":"Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS","volume":"237","author":"Liao","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.celrep.2013.06.018","article-title":"A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model","volume":"4","author":"Chiu","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2024.101312_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","article-title":"Microglia induce motor neuron death via the classical NF-\u03baB pathway in amyotrophic lateral sclerosis","volume":"81","author":"Frakes","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2024.101312_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/j.1471-4159.2007.04677.x","article-title":"Mutant SOD1 G93A microglia are more neurotoxic relative to wild-type microglia","volume":"102","author":"Xiao","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtm.2024.101312_bib19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnen\/63.9.964","article-title":"Activated Microglia Initiate Motor Neuron Injury by a Nitric Oxide and Glutamate-Mediated Mechanism","volume":"63","author":"Zhao","year":"2004","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/glia.20062","article-title":"Increased Cytotoxic Potential of Microglia From ALS-Transgenic Mice","volume":"48","author":"Weydt","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.omtm.2024.101312_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/brb3.75","article-title":"Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1 G93A mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Lerman","year":"2012","journal-title":"Brain Behav."},{"key":"10.1016\/j.omtm.2024.101312_bib22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101312_bib23","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1523\/JNEUROSCI.2037-14.2014","article-title":"Delayed Disease Onset and Extended Survival in the SOD1G93A Rat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex","volume":"34","author":"Thomsen","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","article-title":"Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS","volume":"12","author":"Iannitti","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2024.101312_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101312_bib26","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.4049\/jimmunol.1701172","article-title":"Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation","volume":"199","author":"Sundblad","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2024.101312_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.immuni.2012.05.023","article-title":"Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration","volume":"37","author":"Starossom","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.omtm.2024.101312_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.24618","article-title":"Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model","volume":"79","author":"Stoica","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101312_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtm.2019.12.007","article-title":"Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model","volume":"17","author":"Keeler","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101312_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.26","article-title":"Microglia-specific targeting by novel capsid-modified AAV6 vectors","volume":"3","author":"Rosario","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101312_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/0471142727.mb0901s63","article-title":"Calcium Phosphate Transfection","volume":"63","author":"Kingston","year":"2003","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.omtm.2024.101312_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cells5010012","article-title":"The regulation of NF-\u043aB Subunits by Phosphorylation","volume":"5","author":"Christian","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2024.101312_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/acn3.375","article-title":"Additive amelioration of ALS by co-targeting independent pathogenic mechanisms","volume":"4","author":"Frakes","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib35","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1093\/hmg\/ddx247","article-title":"Ageing as a risk factor for ALS\/FTD","volume":"26","author":"Niccoli","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101312_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12408","article-title":"Projected increase in amyotrophic lateral sclerosis from 2015 to 2040","volume":"7","author":"Arthur","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101312_bib37","unstructured":"FDA Approves New Treatment Option for Patients with ALS | FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-option-patients-als."},{"key":"10.1016\/j.omtm.2024.101312_bib38","unstructured":"Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO\u2122 for the Treatment of ALS | Amylyx https:\/\/www.amylyx.com\/media\/amylyx-pharmaceuticals-announces-fda-approval-of-relyvriotm-for-the-treatment-of-als."},{"key":"10.1016\/j.omtm.2024.101312_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410390203","article-title":"Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis","volume":"39","author":"Gurney","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.expneurol.2008.07.017","article-title":"Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice","volume":"213","author":"Ito","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib41","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101312_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101312_bib43","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtm.2024.101312_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101312_bib45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1523\/JNEUROSCI.0854-15.2016","article-title":"IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1","volume":"36","author":"Gravel","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib46","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.4049\/jimmunol.0901212","article-title":"The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis","volume":"183","author":"D\u2019Ambrosi","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2024.101312_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbi.2010.12.008","article-title":"Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice","volume":"25","author":"Beers","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.omtm.2024.101312_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40478-019-0737-z","article-title":"Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models","volume":"7","author":"Lee","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtm.2024.101312_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/mt.2010.206","article-title":"AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice","volume":"18","author":"Dodge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101312_bib50","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2008.60","article-title":"Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity","volume":"16","author":"Dodge","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101312_bib51","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101312_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-74","article-title":"Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis","volume":"8","author":"Pollari","year":"2011","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.omtm.2024.101312_bib53","unstructured":"HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose - Full Text View - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05136885."},{"key":"10.1016\/j.omtm.2024.101312_bib54","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1016\/j.bbadis.2018.10.013","article-title":"Microglial overexpression of fALS-linked mutant SOD1 induces SOD1 processing impairment, activation and neurotoxicity and is counteracted by the autophagy inducer trehalose","volume":"1864","author":"Massenzio","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.omtm.2024.101312_bib55","unstructured":"#AAN2018 - NP001 Fails to Improve ALS Disease Severity in Phase 2 Trial. https:\/\/alsnewstoday.com\/2018\/04\/27\/np001-fails-improve-als-disease-severity-pulmonary-function-phase-2-trial\/."},{"key":"10.1016\/j.omtm.2024.101312_bib56","unstructured":"Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02794857."},{"key":"10.1016\/j.omtm.2024.101312_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mus.27511","article-title":"Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses","volume":"66","author":"Miller","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2024.101312_bib58","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib59","unstructured":"Minocycline to Treat Amyotrophic Lateral Sclerosis - Full Text View - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00047723."},{"key":"10.1016\/j.omtm.2024.101312_bib60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mcn.2014.12.006","article-title":"Galectin-1 in injured rat spinal cord: Implications for macrophage phagocytosis and neural repair","volume":"64","author":"Gaudet","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omtm.2024.101312_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.expneurol.2005.02.011","article-title":"Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"194","author":"Chang-Hong","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtm.2024.101312_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jneumeth.2010.01.017","article-title":"A new method to isolate microglia from adult mice and culture them for an extended period of time","volume":"187","author":"Moussaud","year":"2010","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.omtm.2024.101312_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T12:56:35Z","timestamp":1733489795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2329050124001281"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101312","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101312"}}